Clinical Trial Update: Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating thalidomide as an anti-angiogenesis therapy in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED